(19)
(11) EP 2 690 951 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.01.2016 Bulletin 2016/01

(45) Mention of the grant of the patent:
26.08.2015 Bulletin 2015/35

(21) Application number: 11785170.9

(22) Date of filing: 20.10.2011
(51) International Patent Classification (IPC): 
A01N 3/02(2006.01)
A01N 27/00(2006.01)
A23L 3/3445(2006.01)
C08J 7/04(2006.01)
C08K 5/101(2006.01)
 A01N 25/34(2006.01)
A23B 7/152(2006.01)
C08F 2/46(2006.01)
C08K 5/01(2006.01)
C08K 5/16(2006.01)
(86) International application number:
PCT/US2011/057017
(87) International publication number:
WO 2012/134539 (04.10.2012 Gazette 2012/40)

(54)

CYCLODEXTRIN COMPOSITIONS, ARTICLES, AND METHODS

CYCLODEXTRINZUSAMMENSETZUNGEN, ARTIKEL UND VERFAHREN

COMPOSITIONS À BASE DE CYCLODEXTRINE, ARTICLES ET PROCÉDÉS ASSOCIÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 27.03.2011 US 201161468041 P

(43) Date of publication of application:
05.02.2014 Bulletin 2014/06

(60) Divisional application:
15180902.7

(73) Proprietor: Cellresin Technologies, LLC
Bloomington, MN 55437 (US)

(72) Inventors:
  • WOOD, Willard E.
    Arden Hills MN 55112 (US)
  • KUDUK, William J.
    Washington, DC 20002 (US)
  • KEUTE, Joseph, S.
    Blaine MN 55449 (US)

(74) Representative: Glas, Holger 
Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3
80335 München
80335 München (DE)


(56) References cited: : 
EP-A2- 1 593 306
US-B2- 6 548 448
 US-A- 6 162 533
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).